FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386898500> ?p ?o ?g. }

• W4386898500 endingPage "e007366" @default.
• W4386898500 startingPage "e007366" @default.
• W4386898500 abstract "Background Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor response rate in both the first-line and second-line treatment of advanced HCC. However, few studies have prospectively evaluated whether TKIs plus anti-PD-1 antibodies could convert unresectable intermediate-advanced HCC into resectable disease. Methods This single-arm, phase II study enrolled systemic therapy-naïve adult patients with unresectable Barcelona Clinic Liver Cancer stage B or C HCC. Patients received oral lenvatinib one time per day plus intravenous anti-PD-1 agents every 3 weeks (one cycle). Tumor response and resectability were evaluated before the fourth cycle, then every two cycles. The primary endpoint was conversion success rate by investigator assessment. Secondary endpoints included objective response rate (ORR) by independent imaging review (IIR) assessment per modified RECIST (mRECIST) and Response Evaluation Criteria in Solid Tumors, V.1.1 (RECIST 1.1), progression-free survival (PFS) and 12-month recurrence-free survival (RFS) rate by IIR per mRECIST, R0 resection rate, overall survival (OS), and safety. Biomarkers were assessed as exploratory objectives. Results Of the 56 eligible patients enrolled, 53 (94.6%) had macrovascular invasion, and 16 (28.6%) had extrahepatic metastasis. The median follow-up was 23.5 months. The primary endpoint showed a conversion success rate of 55.4% (31/56). ORR was 53.6% per mRECIST and 44.6% per RECIST 1.1. Median PFS was 8.9 months, and median OS was 23.9 months. Among the 31 successful conversion patients, 21 underwent surgery with an R0 resection rate of 85.7%, a pathological complete response rate of 38.1%, and a 12-month RFS rate of 47.6%. Grade ≥3 treatment-related adverse events were observed in 42.9% of patients. Tumor immune microenvironment analysis of pretreatment samples displayed significant enrichment of CD8 + T cells (p=0.03) in responders versus non-responders. Conclusion Lenvatinib plus anti-PD-1 antibodies demonstrate promising efficacy and tolerable safety as conversion therapy in unresectable HCC. Pre-existing CD8 + cells are identified as a promising biomarker for response to this regimen. Trial registration number Chinese Clinical Trial Registry, ChiCTR1900023914." @default.
• W4386898500 created "2023-09-21" @default.
• W4386898500 creator A5004967576 @default.
• W4386898500 creator A5010870453 @default.
• W4386898500 creator A5016098902 @default.
• W4386898500 creator A5021319565 @default.
• W4386898500 creator A5021465608 @default.
• W4386898500 creator A5026475999 @default.
• W4386898500 creator A5028514289 @default.
• W4386898500 creator A5035716717 @default.
• W4386898500 creator A5039072735 @default.
• W4386898500 creator A5040595606 @default.
• W4386898500 creator A5043321678 @default.
• W4386898500 creator A5052588320 @default.
• W4386898500 creator A5055420452 @default.
• W4386898500 creator A5060809049 @default.
• W4386898500 creator A5065225564 @default.
• W4386898500 creator A5066446951 @default.
• W4386898500 creator A5067959426 @default.
• W4386898500 creator A5070167890 @default.
• W4386898500 creator A5076296804 @default.
• W4386898500 creator A5078545719 @default.
• W4386898500 creator A5079900226 @default.
• W4386898500 creator A5082789515 @default.
• W4386898500 creator A5083705048 @default.
• W4386898500 creator A5088412694 @default.
• W4386898500 creator A5088822063 @default.
• W4386898500 date "2023-09-01" @default.
• W4386898500 modified "2023-09-27" @default.
• W4386898500 title "Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial" @default.
• W4386898500 cites W1971837077 @default.
• W4386898500 cites W1994193851 @default.
• W4386898500 cites W2501006968 @default.
• W4386898500 cites W2785934310 @default.
• W4386898500 cites W2787358630 @default.
• W4386898500 cites W2885326465 @default.
• W4386898500 cites W2890595557 @default.
• W4386898500 cites W2964256876 @default.
• W4386898500 cites W2969802526 @default.
• W4386898500 cites W2978202966 @default.
• W4386898500 cites W2982214764 @default.
• W4386898500 cites W2995987578 @default.
• W4386898500 cites W2999417355 @default.
• W4386898500 cites W3004894825 @default.
• W4386898500 cites W3029993354 @default.
• W4386898500 cites W3045387409 @default.
• W4386898500 cites W3088397061 @default.
• W4386898500 cites W3117272013 @default.
• W4386898500 cites W3123846806 @default.
• W4386898500 cites W3138484572 @default.
• W4386898500 cites W3149900842 @default.
• W4386898500 cites W3166607747 @default.
• W4386898500 cites W3173141575 @default.
• W4386898500 cites W3208308450 @default.
• W4386898500 cites W3212945766 @default.
• W4386898500 cites W4205285388 @default.
• W4386898500 cites W4205996536 @default.
• W4386898500 cites W4210955410 @default.
• W4386898500 cites W4287472578 @default.
• W4386898500 cites W4297986221 @default.
• W4386898500 doi "https://doi.org/10.1136/jitc-2023-007366" @default.
• W4386898500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37730273" @default.
• W4386898500 hasPublicationYear "2023" @default.
• W4386898500 type Work @default.
• W4386898500 citedByCount "0" @default.
• W4386898500 crossrefType "journal-article" @default.
• W4386898500 hasAuthorship W4386898500A5004967576 @default.
• W4386898500 hasAuthorship W4386898500A5010870453 @default.
• W4386898500 hasAuthorship W4386898500A5016098902 @default.
• W4386898500 hasAuthorship W4386898500A5021319565 @default.
• W4386898500 hasAuthorship W4386898500A5021465608 @default.
• W4386898500 hasAuthorship W4386898500A5026475999 @default.
• W4386898500 hasAuthorship W4386898500A5028514289 @default.
• W4386898500 hasAuthorship W4386898500A5035716717 @default.
• W4386898500 hasAuthorship W4386898500A5039072735 @default.
• W4386898500 hasAuthorship W4386898500A5040595606 @default.
• W4386898500 hasAuthorship W4386898500A5043321678 @default.
• W4386898500 hasAuthorship W4386898500A5052588320 @default.
• W4386898500 hasAuthorship W4386898500A5055420452 @default.
• W4386898500 hasAuthorship W4386898500A5060809049 @default.
• W4386898500 hasAuthorship W4386898500A5065225564 @default.
• W4386898500 hasAuthorship W4386898500A5066446951 @default.
• W4386898500 hasAuthorship W4386898500A5067959426 @default.
• W4386898500 hasAuthorship W4386898500A5070167890 @default.
• W4386898500 hasAuthorship W4386898500A5076296804 @default.
• W4386898500 hasAuthorship W4386898500A5078545719 @default.
• W4386898500 hasAuthorship W4386898500A5079900226 @default.
• W4386898500 hasAuthorship W4386898500A5082789515 @default.
• W4386898500 hasAuthorship W4386898500A5083705048 @default.
• W4386898500 hasAuthorship W4386898500A5088412694 @default.
• W4386898500 hasAuthorship W4386898500A5088822063 @default.
• W4386898500 hasBestOaLocation W43868985001 @default.
• W4386898500 hasConcept C121608353 @default.
• W4386898500 hasConcept C126322002 @default.
• W4386898500 hasConcept C143998085 @default.
• W4386898500 hasConcept C203092338 @default.
• W4386898500 hasConcept C2776264508 @default.
• W4386898500 hasConcept C2776694085 @default.

• next